

***SmartThaw* and *RevitalICE* Featured at International Conference**

CPSI researchers present on the *SmartThaw*[™] cell thawing system and *RevitalICE*[™] reagent at the Cell Culture and Cell Therapy Bioprocessing conference

June 26, 2017

OWEGO, NY -- CPSI Biotech president, Dr. John M. Baust (President and Lead Scientist), presented today at the Cell Culture and Cell Therapy Bioprocessing conference in Philadelphia, PA (June 26-27). CPSI's podium presentation detailed recent studies focused on improving the thawing process and quality of frozen cell and tissue products using CPSI's *SmartThaw*[™] device and *RevitalICE*[™] reagent.

Dr. Baust's presentation featured studies conducted by CPSI researchers on human hematopoietic and mesenchymal stem cells. Commenting on the research, Dr. Baust stated "this study demonstrated that sample quality and processing can be improved using *SmartThaw*[™] and *RevitalICE*[™]. *SmartThaw*[™] provides improved processing of frozen products while in many cases also improving viability post-thaw. Further, the *RevitalICE*[™] post-thaw recovery reagent was shown to give researchers the ability to salvage samples which have been cryopreserved using dated approaches."

Providing further insight, Dr. Kristi Snyder (Director of Operations and Principal Scientist) stated "*SmartThaw*[™] provides a viable alternative to water baths offering a clean, dry and documentable process while delivering improved cell recovery." When asked about *RevitalICE*[™], Dr. Snyder stated "*RevitalICE*[™] is the newest member of the SmartBio platform. *RevitalICE*[™] is a molecular based cell culture media additive designed to modulate a cell's recovery response. *RevitalICE*[™] can be used with any sample which is currently frozen, using any type of preservation media, to more effectively recover samples following thawing, thereby improving sample quality and function." Dr. Baust continued "*RevitalICE*[™] is designed to minimize alterations in cell function thereby improving cryopreservation outcome without front end process changes. This technology offers potential benefit for the billions of samples currently cryopreserved globally today."

Development activities involving *SmartThaw*[™] and *RevitalICE*[™] are ongoing. "We are very excited to take the next steps towards commercialization for both of these technologies. *SmartThaw*[™] will provide a vital link in improving cryopreserved cell handling. We have placed a number of pre-production units with select collaborators to gain end-user feedback to help finalize the product for commercialization. This has been a long process but the information we are collecting on *SmartThaw*[™] has been invaluable. *RevitalICE*[™] remains in the R&D stage, however, reception of the initial data has been very positive" stated Snyder. Currently, CPSI is targeting commercial launch of *SmartThaw*[™] in 2018 with *RevitalICE*[™] following thereafter.

More information on *SmartThaw*[™], *RevitalICE*[™] or any of CPSI's other technologies is available on CPSI's website www.cpsibiotech.com.

About CPSI Biotech - CPSI Biotech, a private, integrative bio/medtech greenhouse company, develops and designs life science research products and cryo-medical devices for applications in cancer, cardiovascular disease treatments and cell therapy bioprocessing. Ongoing R&D and business development activities continue to produce innovative technologies, devices and intellectual property for commercialization, licensing or sales in support of diverse clinical and research applications. By leveraging the innovation, flexibility and R&D strengths of CPSI in combination with the development, commercialization, manufacturing and clinical expertise of partnering organizations, rapid and efficient product development is attainable.

Disclosure Notice: The information contained in this release is as of June 26, 2017. CPSI assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. CPSI's technologies do not have regulatory clearance for commercial sale and are currently intended for "Research Use Only".

With the exception of the historical information contained in this release, this release contains materials and statements related to future business, financial performance, future events and/or developments involving CPSI which constitute forward-looking statements. The matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to, CPSI's ability to develop and market new products, to retain and attract key employees, to obtain regulatory clearances and approvals for its products, to effectively react to other risks and uncertainties, such as fluctuation of quarterly financial results, contract and grants acquisition, reliance on third party manufacturers and suppliers, litigation or other proceedings, economic, competitive, governmental impacts, whether pending patents will be granted or defensible, validity of intellectual property and patents, the ability to license patents, the ability to commercialize developmental products, competition from existing and new products and procedures and CPSI's ability to raise the capital that is required to accomplish the foregoing.

Contacts

CPSI Biotech Contact:

John M Baust, Ph.D., President & Lead Scientist

Kristi Snyder, Ph.D., Director of Operations

contact@cpsibiotech.com